Targeted Oncology
A Podcast on Osimertinib After CRT in Unresectable Stage III EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC): Current and Future Perspectives
By Thanyanan Reungwetwattana, Kristin Ann Higgins, Ignacio Casarini and 1 others.
Abstract
Article full text The above podcast represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, and copyright information, please see the full text online (see “read the peer-reviewed publication” opposite). © The authors, CC-BY-NC 2026
Keywords
- Lung Cancer Treatments and Mutations
- osimertinib
- chemoradiotherapy
- EGFR mutation
- non-small cell lung cancer
- unresectable stage III NSCLC
- EGFR tyrosine kinase inhibitors
- Open access
Source
Published in Targeted Oncology. The abstract is shown as published and remains the work of its authors; read the full article at the source.
Prognia lists this article for reference and education. It is not medical advice. Always read the original and follow current guidelines and local protocols before acting on it.